Tramadol extended-release in the management of chronic pain

Therapeutics and Clinical Risk Management

Volumn 3, Issue 3, 2007, Pages 401-410

  McCarberg, Bill ^a,b  

^a Chronic Pain Management Program   (United States)

^b NONE   (United States)

Author keywords

Chronic pain; COX 2 inhibitor; NSAID; Opioid; Tramadol

Indexed keywords

CENTRAL DEPRESSANT AGENT; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; DEXTROPROPOXYPHENE; MORPHINE; NALOXONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PARACETAMOL; PLACEBO; TRAMADOL;

AGING; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIZZINESS; DROWSINESS; DRUG ABUSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; LIPID DIET; LOW BACK PAIN; MONOTHERAPY; MORBIDITY; MYOFASCIAL PAIN; NAUSEA; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; PAIN ASSESSMENT; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; RESPIRATION DEPRESSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEIZURE; SIDE EFFECT; SLEEP DISORDER; STOMACH ULCER; VISUAL ANALOG SCALE;

EID: 34547698703     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. [ACR] American College of Rheumatology. 2000. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update. Arthritis Rheum, 43:1905-15.
2. [ACR] American College of Rheumatology. 2005. Patient education: Osteoarthritis [online]. Accessed 26 June 2006. URL: http://www.rheumatology.org/public/factsheets/oa↗w.asp?aud=pat.
3. [APF] American Pain Foundation. 2002. Pain facts: An overview of American pain surveys [online]. Accessed 18 September 2006. URL: http://www.painfoundation.org/page.asp?file=Library/PainSurveys.htm.
4. [APS] American Pain Society. 1996. Chronic pain in America - Road-blocks to relief [online]. Accessed 18 Semptember 2006. URL: www.painreliefnetwork.org/wp-content/uploads/PressPacket/ APSRoadblocksToRelief.pdf.
5. Babul N, Noveck R, Chipman H, et al. 2004. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Management, 28:59-71.
6. Caldwell B, Aldington S, Weatherall M, et al. 2006. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med, 99:132-40.
7. [CDC] Centers for Disease Control and Prevention. 2001. Prevalence of disabilities and associated health conditions among adults - United States, 1999. MMWR Morb Mortal Wkly Rep, 50:120-5.
8. [CDC] Centers for Disease Control and Prevention. 2002. Prevalence of self-reported arthritis or chronic joint symptoms among adults - United States, 2001. MMWR Morb Mortal Wkly Rep, 51:948-50.
9. Cherny NI, Portenoy RK. 1994. The management of cancer pain. CA Cancer J Clin, 44:263-303.
10. Cicero TJ, Inciardi JA, Adams EH, et al. 2005. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system 1994-2004. Pharmacoepidemiol Drug Saf, 14:851-9.
11. Cicero TJ, Inciardi JA, Munoz A. 2005. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain, 6:662-72.
12. Cohen JM, Menefee LA, Doghramji K, et al. 2000. Sleep in chronic pain: problems and treatments. Int Rev Psych, 12:115-26.
13. Desmeules JA, Piguet V, Collart L, et al. 1996. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clinical Pharmacol, 41:7-12.
14. Eisendrath SJ. 1995. Psychiatric aspects of chronic pain. Neurology, 45(suppl 9):S26-34.
15. Garcia-Quetglas E, Azanza JR, Sadaba B, et al. 2007. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype. Pharmacol Res, 55:122-30.
16. Glajchen M. 2001. Chronic pain: treatment barriers and strategies for clinical practice. J Am Board Fam Pract, 14:211-18.
17. Gough AC, Miles JS, Spurr NK, et al. 1990. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature, 347:773-6.
18. Hennies HH, Friderichs E, Schneider J. 1988. Receptor binding, analgesic and antitussive potency of tramadol and other selective opioids. Arzneimittlforschung, 38:877-80.
19. Hennies HH, Friderichs E, Wilsmann K, et al. 1982. Effect of the opioid analgesic tramadol on inactivation of norepinephrine and serotonin. Biochem Pharmacol, 31:1654-5.
20. Hopman-Rock M, Kraaimaat FW, Bijlsma JW. 1997. Quality of life in elderly subjects with pain in the hip or knee. Qual Life Res, 6:67-6.
21. Hudson M, Richard H, Pilote L. 2005. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ, 330:1370-6.
22. [JCAHO] Joint Commission on Accreditation of Healthcare Organizations. 2001. Pain: current understanding of assessment, management, and treatments [online]. Accessed 3 October 2006. URL: http://www.npcnow.org/ resources/PDFs/painmonograph.pdf.
23. Kayser V, Besson JM, Guilbaud G. 1991. Effects of the analgesic agent tramadol in normal and arthritic rats: comparison with the effects of different opioids, including tolerance and cross-tolerance to morphine. Eur J Pharmacol, 195:37-45.
24. Kearney PM, Baigent C, Halls H, et al. 2006. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-infiammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ, 332:1302-8. Laborde JM, Powers MJ. 1980. Satisfaction with life for patients undergoing hemodialysis and patients suffering from osteoarthritis. Res Nurs Health, 3:19-24.
25. Leigh TJ, Hindmarch I, Bird HA, et al. 1988. Comparison of sleep in osteoarthntic patients and age and sex matched healthy controls. Ann Rheum Dis, 47:40-2.
26. Mattia C, Coluzzi F. 2005. Tramadol. Focus on musculoskeletal and neuropathic pain. Minerva Anestesiol, 71:565-84.
27. Mattia C, Vanderah T, Raffa RB, et al. 1993. Characterization of the unusual antinociceptive profile of tramadol in mice. Drug Dev Res, 31:1932-43.
28. Menefee LA, Cohen MJ, Anderson WR, et al. 2000. Sleep disturbance and nonmalignant chronic pain: a comprehensive review of the literature. Pain Med, 1:156-72.
29. Menefee LA, Frank ED, Doghramji K, et al. 2000. Self-reported sleep quality and quality of life for individuals with chronic pain conditions. Clin J Pain, 16:290-7.
30. Page J, Henry D. 2000. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an under-recognized public health problem. Arch Intern Med, 160:777-84.
31. Parrott T. 1999. Using opioid analgesics to manage chronic noncancer pain in primary care. J Am Board Fam Pract, 12:293-306.
32. Raffa RB, Friderichs E, Reimann W, et al. 1992. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther, 260:275-85.
33. Raffa RB, Nayak RY, Liao S, et al. 1995. The mechanism of action and pharmacokinetics of tramadol hydrochloride. Rev Cont Pharmacol, 6:485-98.
34. Schnitzer TJ, Kamin M, Olson WH. 1999. Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain: a randomized, double-blind, placebo-controlled study. Arthritis Rheum, 42:1370-7.
35. Stephens J, Laskin B, Pashos C, et al. 2003. The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors. Rheumatology (Oxford), 42(suppl 3):iii40-52.
36. Stewart WF, Ricci JA, Chee E, et al. 2003. Lost productive time and cost due to common pain conditions in the US workforce. JAMA, 290:2443-54.
37. Turner JA, Deyo RA, Loeser JD, et al. 1994. The importance of placebo effects in pain treatment and research. JAMA, 271:1609-14.
38. Ultram PI. 2004. Immediate-release package insert. Raritan, NJ: OrthoMcNeil Inc.
39. Ultram PI. 2006. Extended-release package insert. Raritan, NJ: OrthoMcNeil Inc.
40. Weinstein SM, Laux LF, Thornby JI, et al. 2000. Physicians' attitudes towards pain and the use of opioid analgesics: results of a survey from the Texas Cancer Pain Initiative. South Med J, 93:479-87.
41. Yelin E, Callahan LF; for National Arthritis Data Work Groups. 1995. The economic cost and social and psychological impact of musculoskeletal conditions. Arthritis Rheum, 38:1351-62.